Roche

BioSpecifics names Gould to board of directors

Friday, December 9, 2011 10:48 AM

BioSpecifics Technologies has named George Gould to its board of directors effective December 6, 2011. Gould, an attorney, is principal of George M. Gould and of counsel to Gibbons PC.

More... »

Roche acquires Verum Diagnostica

Monday, December 5, 2011 01:30 PM

Roche has signed an agreement under which it will acquire 100% of Verum Diagnostica, based in Munich, Germany. Verum Diagnostica is a leading company in platelet function testing, the fastest-growing field in the coagulation diagnostics market.

More... »

Roche, PTC sign potential $490m licensing deal

Tuesday, November 29, 2011 01:56 PM

Roche, PTC Therapeutics, and the SMA Foundation, have signed a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) program. SMA is a genetic neuromuscular disorder that causes muscle weakness.

More... »

Roche, BGI develop advanced MHC technology

Monday, November 28, 2011 11:47 AM

More... »

Roche, Cedars-Sinai Medical Center enter five year alliance

Monday, November 21, 2011 04:19 PM

Roche has established a strategic alliance with Cedars-Sinai Medical Center in Los Angeles for the center to operate as a Roche Molecular Center of Excellence (MCOE) for the next five years.

More... »

Report: Clinical trials approved in Russia on course in third quarter

Monday, November 7, 2011 11:26 AM

The number of new studies approved in Russia during the third quarter of 2011 reached last year’s level, with the Ministry of Health and Social Development of the Russian Federation (MoH) approving 132 new clinical trials of all types, including local and bioequivalence studies, according to Synergy Research Group (SynRG), a Russia-based CRO. That’s only two trials below the number approved in the year-ago quarter.

More... »

FDA approves Roche’s hepatitis B test

Monday, October 31, 2011 12:51 PM

Roche has reported that the FDA granted Premarket Approval (PMA) for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay for use on the cobas e 601 analyzer, the immunoassay module of the cobas 6000 analyzer series for mid-volume laboratories. The test represents the final component of the acute panel within the hepatitis test menu for the cobas 6000 series.

More... »

Roche’s Herceptin phase III trial shows positive results

Tuesday, October 18, 2011 09:45 AM

Halozyme Therapeutics has reported that the phase III HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous (IV) infusion. The SC administration takes around 5 minutes to administer whereas the IV formulation (the current standard) takes around 30 minutes to infuse. Since the subcutaneous administration is an injection under the skin it may allow patients to spend less time in hospital receiving their treatment versus the intravenous method. The ready to use formulation may also significantly reduce pharmacy time as no medicine preparation time is required.

More... »

Roche opens new facility in NJ

Tuesday, October 4, 2011 01:15 PM

Roche has opened a new state-of-the-art clinical supply manufacturing facility on its campus in Nutley, N.J. The Roche Center of Excellence produces dosage forms of highly potent compounds for preclinical safety studies, and phase I and II clinical studies. The 17,000 square foot facility houses specialized equipment to process potent compounds into medicines for clinical trials.

More... »

Roche names head of small molecules research

Wednesday, September 14, 2011 11:44 AM

Roche has named Rainer Metternich, PhD, head of small molecules research (SMR), effective immediately. He takes over from Klaus Strein, who will retire from Roche.

More... »